Gaya Herald

DelveInsight’s “Spinal Cord Injury Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of SCI, historical and forecasted epidemiology, as well as the Spinal Cord Injury market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Spinal Cord Injury Market with DelveInsight’s In-Depth Report @ Spinal Cord Injury Market Size

Key Takeaways from the Spinal Cord Injury Market Report

• The SCI market in the 7MM was valued at approximately USD 350 million in 2025 and is projected to expand at a robust CAGR of 18.3% during 2026–2036.

• The leading Spinal Cord Injury companies include AbbVie, Mitsubishi Tanabe Pharma America, Neuroplast, Kringle Pharma, Pharmazz, and others.

• The United States held the largest market share in 2025, contributing approximately USD 150 million (44% of the total 7MM market), supported by a diagnosed prevalent base of around 300,000–310,000 cases, with males representing nearly 80% of the affected population.

• EU4 and the UK recorded a combined market size of USD 160 million in 2025, projected to grow at a CAGR of 10.7% through 2036, with approximately 380,000 traumatic and 150,000 non-traumatic diagnosed prevalent cases reported.

• Japan accounted for approximately USD 50 million of the SCI market in 2025, with falls (around 60,000 cases) and vehicular accidents (around 20,000 cases) as leading causes, and growth is expected to continue, driven by an aging population.

• The emerging pipeline toward 2026 is focused on neuroprotective and regenerative approaches, with Elezanumab (ABT-555) expected to enter the US market by 2028.

Stay ahead in the Spinal Cord Injury Market with DelveInsight’s Strategic Report @ Spinal Cord Injury Market Outlook

Spinal Cord Injury Epidemiology Segmentation in the 7MM

• Total Diagnosed Prevalent Cases of SCI

• Acute (Incident) Cases of SCI

• Gender-specific Diagnosed Prevalent Cases of SCI

• Etiology-specific Diagnosed Prevalent Cases of SCI

• Etiology-specific Diagnosed Prevalent Cases of Traumatic SCI

Spinal Cord Injury Pipeline Analysis

Oremepermin alfa (KP-100IT): Kringle Pharma

An intrathecally administered Hepatocyte Growth Factor (HGF) formulation for acute SCI, designed to target nerve cell protection and facilitate axonal regeneration. A Phase III trial has been completed in Japan, with a follow-up study expected to begin in 2026 ahead of a marketing authorization application; in the US, an IND filing is planned for 2026 ahead of a pivotal Phase III trial. The therapy holds orphan drug designation in Japan (2019) and the US (June 2025), with an EMA ODD application submitted in December 2025.

Elezanumab (ABT-555): AbbVie

A monoclonal antibody that inhibits the RGMA protein, administered via IV infusion for SCI. It is currently in Phase II development and is anticipated to launch in the US by 2028.

Neuro-Cells: Neuroplast

A cell-replacement therapy administered via intrathecal injection for Acute Traumatic Spinal Cord Injury (TSCI), currently in Phase II/III development.

Unasnemab (MT-3921): Mitsubishi Tanabe Pharma America

An RGMA protein inhibitor delivered via IV infusion for Acute Traumatic Cervical Spinal Cord Injury, currently in Phase II development.

STEMIRAC: Nipro Corporation

An autologous mesenchymal stem cell therapy that received conditional approval from Japan’s PMDA in 2018 for neurological symptoms associated with SCI, administered intravenously. As of early 2026, the December 2025 deadline for full approval has passed without a confirmed transition to unconditional approval.

Spinal Cord Injury Market Insights

Current treatment largely emphasizes symptom and pain management rather than disease modification, with Pregabalin (LYRICA) as the sole FDA-approved medication for SCI-related neuropathic pain. Other agents in use include methylprednisolone (acute anti-inflammatory management, though increasingly contested), tramadol, gabapentin, and cannabinoid-based therapies (THC/CBD).

A mechanistically diverse late-stage pipeline spanning neuroprotective, anti-inflammatory, axonal regeneration, and neuromodulatory approaches is expected to drive long-term innovation and sustain market expansion beyond the near-term forecast horizon.

Safety, tolerability, and adherence challenges, particularly in acute care settings and among patients managing long-term paralysis-related comorbidities, remain key determinants of real-world treatment effectiveness and commercial uptake.

Get In-Depth Knowledge on Spinal Cord Injury Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/spinal-cord-injury-market

Spinal Cord Injury Market Outlook

SCI is a devastating, life-altering neurological condition resulting from traumatic or non-traumatic damage to the spinal cord, leading to partial or complete loss of motor, sensory, and autonomic function below the injury level. While most common among young adults due to vehicular accidents and falls, it is increasingly observed among older populations as fall-related injuries grow. Its progressive secondary pathophysiology—triggering inflammation, ischemia, and neuronal cell death—combined with the absence of a curative treatment and the high lifetime cost of care, makes SCI one of the most challenging conditions in modern medicine. Market growth may be tempered by the same broader factors common to emerging therapeutic spaces, including safety/tolerability concerns, pricing, and access challenges.

Scope of the Spinal Cord Injury Market Report

• Coverage: 7MM

• Study Period: 2022–2036

• Forecast Period: 2026–2036

• Spinal Cord Injury Companies: AbbVie, Mitsubishi Tanabe Pharma America, Neuroplast, Kringle Pharma, Pharmazz, and others

• Spinal Cord Injury Therapies: STEMIRAC, Oremepermin alfa, Elezanumab (ABT-555), Neuro-Cells, Unasnemab (MT-3921), and others

• Spinal Cord Injury Market Access & Reimbursements, Unmet Needs and Perspectives

• Spinal Cord Injury SWOT Analysis and KOL Views

Unlock Strategic Insights with DelveInsight’s Comprehensive Spinal Cord Injury Market Report @ Spinal Cord Injury Market Drivers and Barriers

Table of Contents

1. Key Insights

2. Report Introduction

3. SCI Market Overview at a Glance

4. Executive Summary

5. Key Events

6. Disease Background and Overview

7. Epidemiology and Market Methodology

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Emerging Drugs

12. SCI – 7MM Market Analysis

13. Key Opinion Leaders’ Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Related Reports

Spinal Cord Injury – Pipeline Insight, 2026

DelveInsight’s, “Spinal Cord Injury – Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Spinal Cord Injury (SCI) – Epidemiology forecast- 2034

DelveInsight’s “SCI – Epidemiology Forecast – 2034” report delivers an in-depth understanding of SCI, historical and forecasted epidemiology of SCI in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/spinal-cord-injury-market